Our Rare Disease Drug Development Model Cydan is focused on accelerating meaningful therapies for people with rare monogenic, non-oncologic diseases. (cydanco.com)
Like many scientists, we think that gene silencing is the most promising approach to developing meaningful therapies for HD families, and it's gratifying that large companies are willing to make a large financial investment in the therapy. (en.hdbuzz.net)
«We believe Amgen's focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients.» (decode.com)